The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages

Abstract Background Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in...

Full description

Bibliographic Details
Main Authors: Elnaz Shirmohammadi, Seyed-Esmaeil Sadat Ebrahimi, Amir Farshchi, Mona Salimi
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-020-07228-y
id doaj-063f6a93adcf46df8cbce31da550cc64
record_format Article
spelling doaj-063f6a93adcf46df8cbce31da550cc642020-11-25T02:30:10ZengBMCBMC Cancer1471-24072020-09-0120111010.1186/s12885-020-07228-yThe efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophagesElnaz Shirmohammadi0Seyed-Esmaeil Sadat Ebrahimi1Amir Farshchi2Mona Salimi3School of Pharmacy, International Campus, Tehran University of Medical SciencesSchool of Pharmacy, International Campus, Tehran University of Medical SciencesBiopharmaceutical Research Center, AryoGen Pharmed Inc., Alborz University of Medical SciencesPhysiology and Pharmacology Department, Pasteur Institute of IranAbstract Background Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk. Conclusion This study indicates that the effect of Etanercept may be influenced by residing macrophages in tumor microenvironment, and suggests a method to predict the effect of drugs in the presence of stromal cells to guide experimental designs in drug development.http://link.springer.com/article/10.1186/s12885-020-07228-yTNF-αEtanerceptBreast cancerMacrophagesSystems biology
collection DOAJ
language English
format Article
sources DOAJ
author Elnaz Shirmohammadi
Seyed-Esmaeil Sadat Ebrahimi
Amir Farshchi
Mona Salimi
spellingShingle Elnaz Shirmohammadi
Seyed-Esmaeil Sadat Ebrahimi
Amir Farshchi
Mona Salimi
The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
BMC Cancer
TNF-α
Etanercept
Breast cancer
Macrophages
Systems biology
author_facet Elnaz Shirmohammadi
Seyed-Esmaeil Sadat Ebrahimi
Amir Farshchi
Mona Salimi
author_sort Elnaz Shirmohammadi
title The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
title_short The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
title_full The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
title_fullStr The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
title_full_unstemmed The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
title_sort efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2020-09-01
description Abstract Background Interaction between microenvironment and breast cancer cells often is not considered at the early stages of drug development leading to failure of many drugs at later clinical stages. Etanercept is a TNF-alpha inhibitor that has been investigated for potential antitumor effect in breast cancer with conflicting results. Methods Secretome data on MDA-MB-231 cancer cell-line were from public repositories and subjected to gene enrichment analyses. Since MDA-MB-231 cells secrete high levels of Granulocyte-Monocyte Colony Stimulating Factor, which activates macrophages to promote tumor growth, the effect of macrophage co-culturing on anticancer efficacy of Etanercept in breast cancer was evaluated using the Boolean network modeling and in vitro experiments including invasion, cell cycle, Annexin PI, and tetrazolium based viability assays and NFKB activity. Results The secretome profile of MDA-MB-231 cells was similar to the expression of genes following treatment of breast cancer cells with TNF-α. Accordingly, inhibition of TNF-α by Etanercept decreased MDA-MB-231 cell survival, induced apoptosis and cell cycle arrest in vitro and inhibited NFKB activation. The inhibitory effect of Etanercept on cell viability, cell cycle progression, invasion and induction of apoptosis decreased following co-culturing of the cancer cells with macrophages. The Boolean network modeling of the changes in the dynamics of intracellular signaling pathways revealed NFKB activation by secretome of macrophages, leading to a decreased efficacy of Etanercept, suggesting NFKB inhibition as an alternative approach to inhibit cancer cell growth in the presence of macrophage crosstalk. Conclusion This study indicates that the effect of Etanercept may be influenced by residing macrophages in tumor microenvironment, and suggests a method to predict the effect of drugs in the presence of stromal cells to guide experimental designs in drug development.
topic TNF-α
Etanercept
Breast cancer
Macrophages
Systems biology
url http://link.springer.com/article/10.1186/s12885-020-07228-y
work_keys_str_mv AT elnazshirmohammadi theefficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT seyedesmaeilsadatebrahimi theefficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT amirfarshchi theefficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT monasalimi theefficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT elnazshirmohammadi efficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT seyedesmaeilsadatebrahimi efficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT amirfarshchi efficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
AT monasalimi efficacyofetanerceptasantibreastcancertreatmentisattenuatedbyresidingmacrophages
_version_ 1724829566205165568